{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:15Z","timestamp":1792787895149,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Young Talents Program of Sun Yat-sen University Cancer Center"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-04314-5","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T12:54:19Z","timestamp":1756299259000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetics, safety, and efficacy of mixed formulation of fosrolapitant and palonosetron (HR20013) in combination with dexamethasone in patients with solid tumors scheduled for highly emetogenic cisplatin-based chemotherapy: a phase I trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Yuanyuan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengrui","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiquan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"issue":"2","key":"4314_CR1","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/cac2.12397","volume":"43","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Zhao B, Chen G, Chen Y, Liao Z, Zhang H, et al. Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin. Cancer Commun (Lond). 2023;43(2):246\u201356.","journal-title":"Cancer Commun (Lond)"},{"issue":"4","key":"4314_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.5250","volume":"4","author":"DS Wang","year":"2021","unstructured":"Wang DS, Hu MT, Wang ZQ, Ren C, Qiu MZ, Luo HY, et al. Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial. JAMA Netw Open. 2021;4(4): e215250.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"4314_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/annonc\/mdv482","volume":"27","author":"C Weinstein","year":"2016","unstructured":"Weinstein C, Jordan K, Green SA, Camacho E, Khanani S, Beckford-Brathwaite E, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann Oncol. 2016;27(1):172\u20138.","journal-title":"Ann Oncol"},{"issue":"9","key":"4314_CR4","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S1470-2045(15)00035-2","volume":"16","author":"BL Rapoport","year":"2015","unstructured":"Rapoport BL, Chasen MR, Gridelli C, Urban L, Modiano MR, Schnadig ID, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 2015;16(9):1079\u201389.","journal-title":"Lancet Oncol"},{"key":"4314_CR5","unstructured":"Guidelines of Chinese Society of Clinical Oncology (CSCO): Prevention & treatment of nausea and vomiting caused by antitumor therapies (in Chinese). Version 1.0. 2019. https:\/\/www.doc88.com\/p-53247145594833.html. Accessed 19 Dec 2024."},{"key":"4314_CR6","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Antiemesis, version 2. 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed 10 Jun 2025."},{"key":"4314_CR7","unstructured":"China Anti-Cancer Association Committee of Rehabilitation and Palliative Care, China Anti-Cancer Association Committee of Tumor Clinical Chemotherapy, China Anti-Cancer Association Committee of Neoplastic Supportive-Care, Chinese Society of Clinical Oncology Committee of Supportive and Rehabilitative Care, and Zhang Li: [China guidelines on prevention and treatment of nausea and vomiting caused by antitumor therapies (2023 edition)]. Zhonghua Zhong Liu Za Zhi. 2024;46(6):481\u2013501."},{"issue":"2","key":"4314_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102195","volume":"9","author":"J Herrstedt","year":"2024","unstructured":"Herrstedt J, Clark-Snow R, Ruhlmann CH, Molassiotis A, Olver I, Rapoport BL, et al. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open. 2024;9(2): 102195.","journal-title":"ESMO Open"},{"issue":"1","key":"4314_CR9","first-page":"141","volume":"20","author":"H Burmeister","year":"2012","unstructured":"Burmeister H, Aebi S, Studer C, Fey MF, Gautschi O. Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Support Care Cancer. 2012;20(1):141\u20137.","journal-title":"Support Care Cancer"},{"issue":"6","key":"4314_CR10","doi-asserted-by":"publisher","first-page":"e1073","DOI":"10.1002\/onco.13716","volume":"26","author":"M Aapro","year":"2021","unstructured":"Aapro M, Scott\u00e9 F, Escobar Y, Celio L, Berman R, Franceschetti A, et al. Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data. Oncologist. 2021;26(6):e1073\u201382.","journal-title":"Oncologist"},{"key":"4314_CR11","doi-asserted-by":"crossref","unstructured":"Zhou H, Zhao Y, Zhang M, Yao J, Leng S, Li X, et al. Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT. J Clin Oncol. 2025;43(9):1123-36.","DOI":"10.1200\/JCO-24-01308"},{"key":"4314_CR12","unstructured":"U.S. Food & Drug Administration. VARUBI\u2122 (rolapitant) tablets, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206500s000lbl.pdf. Accessed 19 Dec 2024."},{"issue":"12","key":"4314_CR13","first-page":"1600","volume":"57","author":"X Wang","year":"2017","unstructured":"Wang X, Zhang ZY, Powers D, Wang J, Lu S, Arora S, et al. Bioequivalence of Intravenous and Oral Rolapitant: Results From a Randomized. Open-Label Pivotal Study J Clin Pharmacol. 2017;57(12):1600\u20136.","journal-title":"Open-Label Pivotal Study J Clin Pharmacol"},{"issue":"5","key":"4314_CR14","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2217\/14796694.2.5.591","volume":"2","author":"RM Navari","year":"2006","unstructured":"Navari RM. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. Future Oncol. 2006;2(5):591\u2013602.","journal-title":"Future Oncol"},{"key":"4314_CR15","unstructured":"U.S. Food & Drug Administration. AloxiTM (Palonosetron Hydrochloride) Injection. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/21372_aloxi_lbl.pdf. Accessed 23 Jan 2025."},{"issue":"1","key":"4314_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10637-018-0638-1","volume":"37","author":"ZY Zhang","year":"2019","unstructured":"Zhang ZY, Wang J, Kansra V, Wang X. Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects. Invest New Drugs. 2019;37(1):139\u201346.","journal-title":"Invest New Drugs"},{"issue":"5","key":"4314_CR17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/0091270004264641","volume":"44","author":"R Stoltz","year":"2004","unstructured":"Stoltz R, Cyong JC, Shah A, Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol. 2004;44(5):520\u201331.","journal-title":"J Clin Pharmacol."},{"issue":"12","key":"4314_CR18","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1517\/14656566.4.12.2297","volume":"4","author":"SM Grunberg","year":"2003","unstructured":"Grunberg SM, Koeller JM. Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert Opin Pharmacother. 2003;4(12):2297\u2013303.","journal-title":"Expert Opin Pharmacother"},{"key":"4314_CR19","unstructured":"U.S. Food & Drug Administration. EMEND (fosaprepitant) for injection, for intravenous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/022023s021lbl.pdf. Accessed 23 Jan 2025."},{"key":"4314_CR20","unstructured":"U.S. Food & Drug Administration. AKYNZEO\u00ae (fosnetupitant and palonosetron) for injection, for intravenous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/210493Orig1s005lbl.pdf. Accessed 23 Jan 2025."},{"issue":"2","key":"4314_CR21","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00280-006-0385-4","volume":"60","author":"F Puisset","year":"2007","unstructured":"Puisset F, Chatelut E, Sparreboom A, Delord JP, Berchery D, Lochon I, et al. Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect. Cancer Chemother Pharmacol. 2007;60(2):305\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"4314_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/0091270003262950","volume":"44","author":"CR Shadle","year":"2004","unstructured":"Shadle CR, Lee Y, Majumdar AK, Petty KJ, Gargano C, Bradstreet TE, et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol. 2004;44(3):215\u201323.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"4314_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0009-9236(03)00066-3","volume":"74","author":"JB McCrea","year":"2003","unstructured":"McCrea JB, Majumdar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther. 2003;74(1):17\u201324.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"4314_CR24","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1177\/0091270010387792","volume":"51","author":"TC Marbury","year":"2011","unstructured":"Marbury TC, Ngo PL, Shadle CR, Jin B, Panebianco D, Caro L, et al. Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects. J Clin Pharmacol. 2011;51(12):1712\u201320.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"4314_CR25","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1177\/1078155215586824","volume":"22","author":"JJ Natale","year":"2016","unstructured":"Natale JJ, Spinelli T, Calcagnile S, Lanzarotti C, Rossi G, Cox D, et al. Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data. J Oncol Pharm Pract. 2016;22(3):485\u201395.","journal-title":"J Oncol Pharm Pract"},{"key":"4314_CR26","unstructured":"U.S. Food & Drug Administration. FDA Application Review Files (APPLICATION NUMBER: 210493Orig1s000). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210493Orig1s000MultidisciplineR.pdf. Accessed 22 Jan 2025."},{"key":"4314_CR27","doi-asserted-by":"crossref","unstructured":"Yang LQ, Sun XC, Qin SK, Cheng Y, Shi JH, Chen ZD, et al. Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double-blind, phase III study. Eur J Cancer Care (Engl). 2017;26(6):e12668.","DOI":"10.1111\/ecc.12668"},{"issue":"11","key":"4314_CR28","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.clml.2020.06.022","volume":"20","author":"Q Bashir","year":"2020","unstructured":"Bashir Q, Acosta M. Comparative Safety, Bioavailability, and Pharmacokinetics of Oral Dexamethasone, 4-mg and 20-mg Tablets, in Healthy Volunteers Under Fasting and Fed Conditions: A Randomized Open-label, 3-way Crossover Study. Clin Lymphoma Myeloma Leuk. 2020;20(11):768\u201373.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"4314_CR29","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/annonc\/mdy169","volume":"29","author":"L Schwartzberg","year":"2018","unstructured":"Schwartzberg L, Roeland E, Andric Z, Kowalski D, Radic J, Voisin D, et al. Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. Ann Oncol. 2018;29(7):1535\u201340.","journal-title":"Ann Oncol"},{"issue":"14","key":"4314_CR30","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.1002\/cam4.3123","volume":"9","author":"J Chang","year":"2020","unstructured":"Chang J, Chen G, Wang D, Wang G, Lu S, Feng J, et al. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study. Cancer Med. 2020;9(14):5134\u201342.","journal-title":"Cancer Med"},{"issue":"2","key":"4314_CR31","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.21.01315","volume":"40","author":"A Hata","year":"2022","unstructured":"Hata A, Okamoto I, Inui N, Okada M, Morise M, Akiyoshi K, et al. Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE. J Clin Oncol. 2022;40(2):180\u20138.","journal-title":"J Clin Oncol"},{"issue":"22","key":"4314_CR32","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.1002\/cncr.32429","volume":"125","author":"S Sugawara","year":"2019","unstructured":"Sugawara S, Inui N, Kanehara M, Morise M, Yoshimori K, Kumagai T, et al. Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Cancer. 2019;125(22):4076\u201383.","journal-title":"Cancer"},{"key":"4314_CR33","unstructured":"U.S. Food and Drug Administration: EMEND (fosaprepitant) for injection, for intravenous use: Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022023s019lbl.pdf. Accessed 19 Dec 2024."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04314-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04314-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04314-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T04:45:22Z","timestamp":1757479522000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04314-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4314"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04314-5","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol and all amendments were approved by the Ethics Committee of Sun Yat-sen University Cancer Center (A2022-093-01), Zhejiang Provincial People\u2019s Hospital (2022-084), China-Japan Union Hospital of Jilin University (20221125002), and The First Affiliated Hospital and Clinical Medical College of Henan University of Science and Technology (2022-0225). The study was conducted following the Declaration of Helsinki, Good Clinical Practice, and local laws and regulatory requirements. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Tengrui Yin, Ranran Zhang, and Yuanyuan Huang reported being employed by Fujian Shengdi Pharmaceutical Co., Ltd. No other disclosures were reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"501"}}